BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chiesi Farmaceutici readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Chiesi Farmaceutici's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05710692-10978@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:pegunigalsidase alfa: Phase 2/3 readout est. (NCT05710692)
DESCRIPTION:pegunigalsidase alfa\, phase 2/3\, Fabry Disease.\nStudy: Study
  to Evaluate the Safety\, PK\, PD\, and Efficacy of PRX-102 in Japanese Pa
 tients With Fabry Disease\nEstimated primary completion: October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pegunigalsidase-alfa#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0571069
 2
URL:https://assetmemo.bio/drug/pegunigalsidase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679270-129@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Myalept (metreleptin): Phase 3 readout est. (NCT06679270)
DESCRIPTION:Myalept (metreleptin)\, phase 3.\nStudy: Open-label Extension S
 tudy to Evaluate Metreleptin in Patients With Partial Lipodystrophy\nEstim
 ated primary completion: March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/metreleptin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06679270
URL:https://assetmemo.bio/drug/metreleptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06328608-10978@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:pegunigalsidase alfa: Phase 2/3 readout est. (NCT06328608)
DESCRIPTION:pegunigalsidase alfa\, phase 2/3\, Fabry Disease.\nStudy: A Stu
 dy to Learn About the Safety and Effects of the Study Drug PRX-102 in Chil
 dren and Adolescents With Fabry Disease\nEstimated primary completion: Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pegunigals
 idase-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06328608
URL:https://assetmemo.bio/drug/pegunigalsidase-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07546981-4243@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20281017
DTEND;VALUE=DATE:20281018
SUMMARY:Trimbow (Beclomethasone dipropionate/formoterol fumarate/glycopyrro
 late): Phase 3 readout est. (NCT07546981)
DESCRIPTION:Trimbow (Beclomethasone dipropionate/formoterol fumarate/glycop
 yrrolate)\, phase 3\, Asthma.\nStudy: Efficacy and Safety of CHF 5993 100/
 6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Do
 ses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonist
 s\nEstimated primary completion: 17 October 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/beclomethasone-dipropionate-formoterol-fumara
 te-glycopyrrolate#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07546981
URL:https://assetmemo.bio/drug/beclomethasone-dipropionate-formoterol-fumar
 ate-glycopyrrolate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
